Initiator Pharma starts dosing of last the patients in the IPED2015 Clinical Trial
(WorldNews Denmark)

Initiator Pharma A/S, a biotech company that is developing a novel treatment of erectile dysfunction, today announced that the dosing of the last patients in clinical Phase 2a Proof-of-Concept trial with IPED2015 has started. The study data analysis will be initiated shortly and our current best estimate for releasing draft data from the study is during December 2019. The conductance of the study, a randomized, double-blind, placebo-controlled, erotic movie challenge, cross-over trial studying the efficacy and...